Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOXD3 Regulates VISTA Expression in Melanoma.
Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. Rosenbaum SR, et al. Among authors: chervoneva i. Cell Rep. 2020 Jan 14;30(2):510-524.e6. doi: 10.1016/j.celrep.2019.12.036. Cell Rep. 2020. PMID: 31940493 Free PMC article.
Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.
Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Sato T, et al. Among authors: chervoneva i. J Clin Oncol. 2008 Nov 20;26(33):5436-42. doi: 10.1200/JCO.2008.16.0705. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838710 Free PMC article. Clinical Trial.
Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine.
Hauzenberger JR, Hipszer BR, Loeum C, McCue PA, DeStefano M, Torjman MC, Kaner MT, Dinesen AR, Chervoneva I, Pieber TR, Joseph JI. Hauzenberger JR, et al. Among authors: chervoneva i. Diabetes Technol Ther. 2017 Nov;19(11):641-650. doi: 10.1089/dia.2017.0175. Epub 2017 Oct 5. Diabetes Technol Ther. 2017. PMID: 28981324 Free PMC article.
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: chervoneva i. Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Cancer Discov. 2018. PMID: 29496664 Free PMC article.
ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. Capparelli C, et al. Among authors: chervoneva i. Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16. Cancer Res. 2018. PMID: 30115691 Free PMC article.
Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.
Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. Teh JLF, et al. Among authors: chervoneva i. Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. Cancer Discov. 2018. PMID: 30510016 No abstract available.
139 results